SECsense Logo

scPharmaceuticals Inc. 10-Q/A Amendment: Key Executive Trading Disclosures

$SCPH
Form 10-Q/A
Filed on: 2024-12-31
Source
scPharmaceuticals Inc. 10-Q/A Amendment: Key Executive Trading Disclosures

Here's the key information extracted from the provided section of the financial report for scPharmaceuticals Inc.:

  1. Company Identification:
  • Name: scPharmaceuticals Inc.
  • CIK Number: 0001604950
  • Address: 25 Mall Road, Suite 203, Burlington, MA 01803
  • Phone: 617-517-0730
  • Common Stock: Par value $0.0001 per share, traded under the ticker SCPH on NASDAQ.
  1. Filing Details:
  • Filing Type: Amendment No. 1 on Form 10-Q/A.
  • Original Filing Date: November 13, 2024.
  • Quarter Ended: September 30, 2024.
  • Amendment Purpose: To amend Part II, Item 5 ("Other Information") by adding disclosures related to "Rule 10b5-1 trading arrangements" entered into by:
    • John H. Tucker (President and CEO).
    • Rachael Nokes (Chief Financial Officer).
  1. Regulatory Compliance:
  • New certifications by the principal executive officer and principal financial officer are included as exhibits in this Amendment, per Rule 12b-15 of the Securities Exchange Act.
  • No financial statements were included in this Amendment; thus, certain certification paragraphs were omitted.
  1. No Changes to Financials:
  • This Amendment does not amend or update financial statements or reflect events occurring after the Original Filing.
  • It should be read together with the Original Filing and other SEC filings by the Company.
  1. Rule 10b5-1 Arrangements:
  • Rule 10b5-1 Adopted: No (false).
  • Non-Rule 10b5-1 Arrangements Adopted: No (false).
  • Rule 10b5-1 Arrangements Terminated: No (false).
  • Non-Rule 10b5-1 Arrangements Terminated: No (false).

This summary highlights the essential aspects of the filing, regulatory compliance, and any changes or affirmations regarding trading arrangements by company executives.